Key result
Serum biomarkers of myocardial necrosis, left ventricular dysfunction, and systemic inflammation will be evaluated as predictors of left ventricular remodeling at 6 months post-myocardial infarction in this study protocol.
Why the study?
Heart failure commonly stems from left ventricular systolic dysfunction caused by myocardial ischemia, with cardiac remodeling serving as a major compensatory mechanism.
Do acute-phase serum biomarkers (hs-troponin, NT-proBNP, hsCRP, interleukins) predict left ventricular remodeling at 6 months post-myocardial infarction?
Do acute-phase serum biomarkers (hs-troponin, NT-proBNP, hsCRP, interleukins) predict left ventricular remodeling at 6 months post-myocardial infarction?
This study protocol outlines a prospective cohort to evaluate whether acute-phase serum biomarkers can predict adverse left ventricular remodeling at 6 months post-myocardial infarction using speckle tracking echocardiography.
Heart failure is a clinical syndrome that appears as a consequence of a structural disease, and the most common cause of left ventricular systolic dysfunction results from myocardial ischemia. Cardiac remodeling and neuroendocrine activation are the major compensatory mechanisms in heart failure. The main objective of the study is to identify the association between serum biomarkers illustrating the extent of myocardial necrosis (highly sensitive troponin as-says), left ventricular dysfunction (NT-proBNP), and systemic inflammatory response (illustrated via serum levels of hsCRP and interleukins) during the acute phase of a myocardial infarction, and the left ventricular remodeling process at 6 months following the acute event, quantified via speckle tracking echocardiography. The study will include 400 patients diagnosed with acute myocardial infarction without signs and symptoms of heart failure at the time of enrollment that will undergo a complex clinical examination and speckle tracking echocardiography. Serum samples from the peripheral blood will be collected in order to determine the inflammatory serum biomarkers. After 6 months, patients will be divided into 2 groups according to the development of ventricular remodeling, quantified by speckle tracking echocardiography: group 1 will consist of patients with a remodeling index lower than 15%, and group 2 will consist of patients with a remodeling index higher than 15%. All clinical and imaging data obtained at the baseline will be compared between these two groups in order to determine the features associated with a higher risk of deleterious ventricular remodeling and heart failure.
No takes yet. Share an insight, caveat, or question.
Cîrneală et al. (2019) studied Acute Myocardial Infarction (n=400). Serum biomarkers (highly sensitive troponin, NT-proBNP, hsCRP, interleukins) was evaluated on Left ventricular remodeling at 6 months (remodeling index >15%). Serum biomarkers of myocardial necrosis, left ventricular dysfunction, and systemic inflammation will be evaluated as predictors of left ventricular remodeling at 6 months post-myocardial infarction in this study protocol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: